Eddie Hickman
Stock Analyst at Guggenheim
(3.80)
# 665
Out of 4,931 analysts
16
Total ratings
50%
Success rate
12.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $78 → $84 | $46.61 | +80.22% | 8 | May 2, 2025 | |
| PMN ProMIS Neurosciences | Reiterates: Buy | $6 | $0.59 | +916.78% | 2 | Apr 1, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $20 → $22 | $12.06 | +82.42% | 1 | Mar 13, 2025 | |
| GHRS GH Research | Initiates: Buy | $32 | $12.00 | +166.67% | 1 | Mar 13, 2025 | |
| CYBN Cybin | Initiates: Buy | $35 | $7.56 | +362.96% | 1 | Mar 13, 2025 | |
| OTLK Outlook Therapeutics | Reiterates: Buy | $12 | $1.82 | +561.16% | 3 | Jan 17, 2025 |
Tarsus Pharmaceuticals
May 2, 2025
Maintains: Buy
Price Target: $78 → $84
Current: $46.61
Upside: +80.22%
ProMIS Neurosciences
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $0.59
Upside: +916.78%
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $12.06
Upside: +82.42%
GH Research
Mar 13, 2025
Initiates: Buy
Price Target: $32
Current: $12.00
Upside: +166.67%
Cybin
Mar 13, 2025
Initiates: Buy
Price Target: $35
Current: $7.56
Upside: +362.96%
Outlook Therapeutics
Jan 17, 2025
Reiterates: Buy
Price Target: $12
Current: $1.82
Upside: +561.16%